The global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market is expected to generate a market value of US$ 3 billion in 2023 and a market value of US$ 4.89 billion by 2033, with a CAGR of 5% from 2023 to 2033. From 2018 to 2022, the market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics grew at a 3.5% CAGR.

According to a new market research report published by Future Market insights, the global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market is expected to grow at a CAGR of 5% from 2023 to 2033, reaching a market size of US$ 4.89 Billion by 2033.

Unlock valuable insights today. Grab our sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16811

The report also highlights the growing awareness of FSGS, with improved diagnosis and treatment of the disease. This has led to an increased demand for FSGS therapeutics, driving market growth. Additionally, the report suggests that favorable reimbursement policies for FSGS therapeutics in many countries have increased patient access to these drugs, driving market growth.

North America is expected to account for the largest share of the FSGS therapeutics market, with increasing investments in healthcare and government initiatives supporting the development and commercialization of FSGS therapeutics. The Asia-Pacific region is also expected to experience significant growth in the FSGS therapeutics market, driven by the increasing prevalence of FSGS and growing awareness of the disease.

Key Takeaways:

• From 2018 to 2022, the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market grew at a CAGR of 3.5%.
• The global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market is expected to grow with a 5% CAGR during 2023 to 2033.
• As of 2033, the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market is expected to reach US$ 4.89 Billion.
• According to the FMI analysis, the immunosuppressive agents segment accounts for the largest market share.
• North America is expected to possess 40% market share for the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market.
• The East South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Focal Segmental Glomerulosclerosis (FSGS) Therapeutics.” says an FMI analyst

Market Competition:

Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.

• In May 2022, Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review. Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.

The NDA submission for sparsentan is based on results from the ongoing Phase 3 PROTECT Study, which is one of the largest interventional studies conducted in IgAN to date. The study evaluated sparsentan in 404 patients with persistent proteinuria and met its pre-specified interim primary efficacy endpoint, which measured changes in proteinuria compared to the active control irbesartan.

More Insights Available:

FMI, in its new offering, presents an unbiased analysis of the global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Disease Type, Drug Class, Treatment Region.

Key Companies:

Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc

Key Segments:

Disease Type:

• Primary FSGS
• Secondary FSGS

Drug Class:

• Corticosteroids
• Immunosuppressive Drugs
• Plasmapheresis
• ACE Inhibitors and ARBs
• Diuretics

Treatment:

• Drug Therapy
• Dialysis
• Kidney Transplant

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East Africa